HemaXellerate is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.

Intellectual property covering the HemaXellerate product include US Provisional Patent applications 61/648898 - Acceleration of Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells and 61/670791 - Treatment of Hematopoietic Disorders filed by Regen, as well as an option to exclusively license issued US Patent #6,821,513.